Back to Journals » Cancer Management and Research » Volume 1

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer

Authors Lorch J

Published 3 November 2009 Volume 2009:1 Pages 151—154

DOI https://doi.org/10.2147/CMAR.S5134

Review by Single-blind

Peer reviewer comments 2


Jochen H Lorch

Dana Farber Cancer institute, Boston, MA, USA

Abstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic setting. This review summarizes the most important developments of the recent past and provides an overview of newer developments.

Keywords: squamous cell cancer, head, neck, epidermal growth factor receptor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]